Marc Goodman is a Senior Research Analyst at Leerink Partners covering Neuroscience and Ophthalmology.
Prior to joining the Firm in 2018, Marc was most recently a Managing Director and U.S. Healthcare Analyst at UBS Investment Bank, where he focused on large-cap and specialty pharmaceuticals sectors. Prior to UBS, he covered specialty pharmaceuticals and generics sectors for over 15 years as a Managing Director at Crédit Suisse AG and as an Executive Director at Morgan Stanley.
Marc has been ranked by Institutional Investor as a top analyst in Specialty Pharmaceuticals for well over a decade and has also expanded his coverage and interests into global and emerging biopharmaceutical companies in recent years.
He earned his MBA from The Ohio State University and his B.A. in Economics from Tufts University.